The Ocular Drug Delivery Market Size and Growth impelled by growing prevalence of eye disorders and rising research on ocular drug delivery; while implantable ocular drug delivery systems segment to grow at highest CAGR during 2021–2028.

New York, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Ocular Drug Delivery Market: Key Insights
According to our new research study on "Ocular Drug Delivery Market to 2028 – Global Analysis and Forecast – by Technology, Formulation Type, Disease Type, End User, and Geography," the Ocular Drug Delivery Market Size is projected to reach US$ 27,016.20 million by 2028 from US$ 16,404.32 million in 2021; it is expected to grow at a CAGR of 7.4% from 2021 to 2028.

Ocular Drug Delivery Market: Competitive Landscape
AbbVie Inc.; Bausch Health Companies Inc.; Taiwan Liposome Company, Ltd.; Ocular Therapeutix, Inc., Graybug Vision, Inc.; Alimera Sciences, Inc.; Envisia Therapeutics; Novartis AG; EyeGate Pharmaceuticals, Inc; and Clearside Biomedical, Inc. are among the key companies operating in the ocular drug delivery market. The major market players are focusing on the launch of new products, expansion and diversification of market presence, and acquisition of new customer base, thereby tapping prevailing business opportunities.  

In March 2020, AbbVie (Allergan plc.) received FDA approval for DURYSTA (bimatoprost implant). It is the first and only intracameral biodegradable sustained-release implant to lower intraocular pressure in open-angle glaucoma or ocular hypertension patients.

In December 2020, EyeGate Pharmaceuticals, Inc. acquired Panoptes Pharma, a privately-held clinical-stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases.

Get Exclusive Sample Pages of Ocular Drug Delivery Market Size - COVID-19 Impact and Global Analysis with Strategic Insights at https://www.theinsightpartners.com/sample/TIPRE00004206/

North America to Dominate Ocular Drug Delivery Market:
The North America ocular drug delivery market is further segmented into the US, Canada, and Mexico. The US is the most significant contributor to the market in this region. The leading position of North America in the global ocular drug delivery market is primarily attributed to product awareness, an increase in the prevalence of eye diseases, and the presence of major market players in the region. Further, the aging population in the US is likely to increase the incidence of eye diseases, which will eventually drive the adoption of ocular drug delivery products in the country. For instance, as per the Population Reference Bureau 2019, the number of individuals in the US aged 65 and older is estimated to double from 52 million in 2018 to around 95 million by 2060, and the 65 and more age group's share of the total population will increase from 16% to 23%. This aged population is highly vulnerable to eye conditions. For instance, as per the American Academy of Ophthalmology 2019 study, an estimated 7.32 million people aged 70–75 will be affected by primary open-angle glaucoma (POAG) by 2050 in the US.     

The Asia Pacific ocular drug delivery market is mainly represented by China, Japan, India, Australia, and South Korea. The rest of the countries in Asia Pacific also contribute to the regional market growth. The market in this region is driven by rising incidence of visual impairments, growing geriatric population in the region, and increasing number of pharmaceutical and biotech companies in this region. China is facing similar problems regarding eye diseases or disorders. In April 2018, the country reported that approximately 720 million people were affected by short-sightedness. The country also has the largest number of people with uncorrected poor vision, and it is expected the numbers are likely to boom in the coming future. Also, the country has a large number of ophthalmologists. There are approximately 28,000 ophthalmologists, which are five times more than the World Health Organization's guidelines. Therefore, considering the factors mentioned above, the market for ocular drug delivery is expected to propel during the forecast period.

The leading cause of blindness or low vision across the globe is cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, and unaddressed refractive error. The majority of the global population have or had some eye disorder in their lifetime. As per the World Health Organization (WHO) report "Blindness and vision impairment" published in February 2021, around 2.2 billion people worldwide have a near or distance vision impairment. It has also estimated that the leading cause of vision loss or low vision is cataract (94 million) and uncorrected refractive errors (88.4 million). Further, the other common causes of vision loss are glaucoma (7.7 million), corneal opacities (4.2 million), diabetic retinopathy (3.9 million), and trachoma (2 million).

Download Sample PDF Brochure of Ocular Drug Delivery Market Size and Growth Research Report at https://www.theinsightpartners.com/sample/TIPRE00004206/

According to the National Eye Institute (NEI), in the US, the number of people with cataracts is expected to double from 24.4 million in 2010 to about 50 million in 2050. Similarly, as per the Factsheet Glaucoma: Facts & Figures 2019, over 3 million people in the US were living with glaucoma.  Moreover, as per the Canadian Survey on Disabilities 2017, 1.5 million Canadians had a sight loss, and around 5.59 million had an eye disease which could further lead to sight loss.

Additionally, as per the Royal National Institute of Blind People in 2017, in the UK, there were around 350,000 people registered as blind and partially sighted; about 173,735 were registered for severely sight impaired; and 176,125 were registered for sight-impaired.    

Ocular Drug Delivery Market: Segmental Overview
Based on technology, the ocular drug delivery market is segmented into implantable ocular drug delivery systems, particulate drug delivery systems, nano-particle drug delivery system, and others. The implantable ocular drug delivery systems segment would account for the largest market share in 2021, and the same segment is anticipated to register the highest CAGR during the forecast period.

Based on formulation type, the ocular drug delivery market is segmented into liposomes and nanoparticles, solution, emulsion, suspension, and ointment. The solution segment would hold the largest share of the market in 2021, and it is estimated to register the highest CAGR in the market during 2021–2028. The growth of the solution segment is attributed to the increasing adoption of ocular drug delivery systems in solution forms, like eye drops and injectables.

Based on disease type, the ocular drug delivery market is segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, and others. The cataract segment would account for the largest market share in 2021. The market for this segment is estimated to grow at the highest CAGR from 2021 to 2028.

Order a Copy of Ocular Drug Delivery Market Size, Share, Strategic Insights and Forecasts 2021-2028 Research Report at https://www.theinsightpartners.com/buy/TIPRE00004206/

Based on end user, the ocular drug delivery market is segmented into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment would hold the largest share of the market in 2021, while the ophthalmic clinics segment is estimated to register the highest CAGR in the market during the forecast period. 

Impact of COVID-19 Pandemic on Ocular Drug Delivery Market:
The COVID-19 pandemic has become the most significant challenge across the world. As this pandemic has stressed healthcare systems across the globe, prioritizing the limited resources was essential to minimize hospital admissions. However, despite increased demand for ocular therapeutics such as eye drops, ointment, and suspension, there was a shortage of these products as new consumers entered the market. Manufacturers are also experiencing raised prices and potential shortages of raw ingredients due to supply restrictions. However, as the restrictions have been lifted and businesses are resuming, the demand-supply variables are coming back to normal. This will offer several growth prospects for ocular drug delivery therapeutics.   
   

Browse Related Reports:
Liposome Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Others); Technology ( Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, Lysolipid Thermally Sensitive Liposome (LTSL)); Application (Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy)

Implantable Drug Delivery Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion Pumps); Technology (Biodegradable Implants, Non-biodegradable Implants); Application (Ophthalmology, Oncology, Cardiovascular, Birth control, Opioid use disorder, Others)

Liposome Assisted Drug Delivery Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others); Application (Fungal Infection Therapy, Cancer and Tumor Therapy, Others)

Subcutaneous Drug Delivery Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product Type (Fillable Injectable, Prefilled Injectable) ; Type (Disposable subcutaneous drug delivery injectable, Reusable subcutaneous drug delivery injectable) ; Technology type (Jet, Spring, Gas) ; Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug store, Online Pharmacies)

Pulmonary Drug Delivery Devices/Systems Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Capsule Endoscopy, Drug Delivery, Patient Monitoring) By Application (Asthma, COPD, Allergic Rhinitis, Cystic Fibrosis and Others) and By End User (Hospitals & Clinics, Research Institutes and Home Healthcare)

Next Generation Diabetes Therapy And Drug Delivery Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas); Indication (Type 1 Diabetes, Type 2 Diabetes); End-User (Diagnostics/Clinics, ICUs, Home Healthcare) and Geography

Drug Delivery Systems Market to 2027- Global Analysis and Forecasts by Route of Administration (Oral, Transmucosal, Injectable, Topical, Implantable, and Ocular); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies); Application (Hospitals & Clinics, Home Care Settings, and Others) and Geography

Pharmaceutical Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Route of Administration (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery); Application (Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory. Diseases, Central Nervous System Disorders, Autoimmune Diseases, and Other Diseases); End User (Hospitals, Home Care Settings, ASC/Clinics, Other End Users), and Geography

Transmucosal Drug Delivery Systems Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Type (Passive Transdermal Drug Delivery, and Active Transdermal Drug Delivery); End User (Hospitals, Clinics and Others)

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release - https://www.theinsightpartners.com/pr/ocular-drug-delivery-market

Connect With Us on:
LinkedIn: https://www.linkedin.com/company/7591674/admin/
Twitter: https://twitter.com/tipmarkettrends
Facebook: https://www.facebook.com/theinsightpartners/
YouTube: https://www.youtube.com/c/TheInsightPartners
RSS/Feeds: https://www.theinsightpartners.com/feed/ | https://www.prnewswire.com/news/the-insight-partners/